Fig. 1From: Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancerCorrelation between biomarker variations and time to progression. For each biomarker, the number of patients with a biomarker event (biomarker increase or mutation emergence) according to the time of progression (PD) is reportedBack to article page